Option chain shows key data for Hansa Biopharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Hansa Biopharma.

Hansa Biopharma (OTC:HNSBF) Stock, Option Chain

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ABCP

AEMD

AFTM

AGFAF

ALTAF

AMRK

ANDR

APAFF

ARXXL

ASPCF

BLOZF

BOSQF

BOTH

BSRC

BTCY

BTSC

BVLDF

BVNNF

CADMF

CBLRF

CLIRF

CLOW

CMGHF

CNBX

CNONF

CONN

COTE

CPNFF

CRNT

CTRM

CTVIF

CWBHF

DAUGF

DOGZ

ELGX

ENDV

ENRT

EVIO

FAMI

FCGD

GALOF

GCFB

GFTX

GGBXF

GLBS

GOSS

GRPBF

GTEC

HEMP

HHPHF

HNSBF

IGRW

INAP

IQST

JILL

JUTOY

KGET

KOPN

LATF

LIXT

LQDA

LTMCF

MDCN

MMJJF

MOGLF

NMHLY

NMKEF

NSUPF

NVSGF

NXTTF

NZRIF

OTEL

OTOW

OZSC

PAOTF

PHUN

PIXY

PMTS

PRRE

PSIX

PTOTF

QRTEA

QRTEB

RETC

RGLSF

RNSFF

SCNNF

SEED

SHLO

SNAVF

SNIRF

SXTC

TCHH

TISUQ

TLRY

Stocks That Hit 52-Week Lows On Tuesday

ACWRF

ADMP

ALLEGIANT GOLD LTD by Allegiant Gold Ltd.

AUXXF

AVPMF

BBAR

BKTPF

BKYI

BTKRF

CEPU

CGTFF

CMCLF

CNPOF

CREX

DKGH

DNJR

DVCR

EGRNY

EMESQ

EOPT

FISOF

GGAL

GLDFF

GTXO

GYNAF

HCCC

HYSR

ITKG

IVITF

JAPAF

LDSYF

LGF-B

LMNR

MFCSF

MGAFF

MJARF

MKTAY

MMDM

MTZPY

NSANF

NSANY

NSPDF

NXES

OLLI

OSBC

OVCHY

PAHC

PDCO

PTNUF

RLLVF

SCOO

SGBX

SPECTRUM GLOBAL SOLUTIONS by Spectrum Global Solutions, Inc.

SGSI

SNNVF

SRHIF

SWDBY

TATT

Telecom Argentina Stet - France Telecom S.A.

THDDY

TTSRF

TWMC

VSBGF

WSTL

XREG

SPPDF

SENS

INDXF

EXSPF

RZREF

MCUIF

QZMRF

Stocks That Hit 52-Week Lows On Thursday

Hansa Biopharma AB

Press Releases

Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial

Earnings

Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results

Hansa Biopharma to Attend Truist Securities BioPharma Symposium

Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome

Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease

Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome

Small Cap

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

Hansa Biopharma publishes 2024 Annual and Sustainability Reports

SRPT

Hansa Biopharma

Comments

Hansa Biopharma

Hansa Biopharma (HNSBF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga